SG160212A1 - Process for the preparation of n-substituted 2-cyanopyrrolidines - Google Patents

Process for the preparation of n-substituted 2-cyanopyrrolidines

Info

Publication number
SG160212A1
SG160212A1 SG200716949-3A SG2007169493A SG160212A1 SG 160212 A1 SG160212 A1 SG 160212A1 SG 2007169493 A SG2007169493 A SG 2007169493A SG 160212 A1 SG160212 A1 SG 160212A1
Authority
SG
Singapore
Prior art keywords
reacting
preparation
resultant compound
substituted
halogen
Prior art date
Application number
SG200716949-3A
Other languages
English (en)
Inventor
Frank Schafer
Gottfried Sedelmeier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33301223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG160212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0308854A external-priority patent/GB0308854D0/en
Priority claimed from GB0311836A external-priority patent/GB0311836D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG160212A1 publication Critical patent/SG160212A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG200716949-3A 2003-04-16 2004-04-15 Process for the preparation of n-substituted 2-cyanopyrrolidines SG160212A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308854A GB0308854D0 (en) 2003-04-16 2003-04-16 Organic compounds
GB0311836A GB0311836D0 (en) 2003-05-22 2003-05-22 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
SG160212A1 true SG160212A1 (en) 2010-04-29

Family

ID=33301223

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200716949-3A SG160212A1 (en) 2003-04-16 2004-04-15 Process for the preparation of n-substituted 2-cyanopyrrolidines

Country Status (31)

Country Link
US (1) US7375238B2 (da)
EP (1) EP1620396B1 (da)
JP (1) JP4672647B2 (da)
KR (1) KR101192538B1 (da)
AR (1) AR044019A1 (da)
AU (2) AU2004230245B2 (da)
BR (1) BRPI0409471B8 (da)
CA (1) CA2520128C (da)
CL (1) CL2004000804A1 (da)
CO (1) CO5700735A2 (da)
CY (1) CY1116008T1 (da)
DK (1) DK1620396T3 (da)
EC (1) ECSP056093A (da)
ES (1) ES2531084T3 (da)
HK (1) HK1087695A1 (da)
HR (1) HRP20150163T1 (da)
IL (1) IL170887A (da)
IS (1) IS2979B (da)
MA (1) MA27765A1 (da)
MX (1) MXPA05011073A (da)
MY (1) MY139476A (da)
NO (1) NO333251B1 (da)
NZ (1) NZ542899A (da)
PE (2) PE20050021A1 (da)
PL (1) PL1620396T3 (da)
PT (1) PT1620396E (da)
RU (1) RU2369598C2 (da)
SG (1) SG160212A1 (da)
SI (1) SI1620396T1 (da)
TW (1) TWI359135B (da)
WO (1) WO2004092127A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050021A1 (es) 2003-04-16 2005-03-15 Novartis Ag Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
RS57561B1 (sr) 2004-01-20 2018-10-31 Novartis Ag Formulacija dobijena direktnom kompresijom i proces za njeno dobijanje
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
JP2009503108A (ja) * 2005-08-04 2009-01-29 ノバルティス アクチエンゲゼルシャフト ビルダグリプチン塩
JP5165584B2 (ja) * 2006-11-29 2013-03-21 田辺三菱製薬株式会社 Ｎ−（ｎ’−置換グリシル）−２−シアノピロリジン誘導体の製法
WO2008084383A2 (en) * 2007-01-10 2008-07-17 Medichem, S.A. Process for preparing vildagliptin
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
EP2459531B1 (en) * 2009-07-31 2019-09-11 KRKA, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
HUP0900638A2 (en) * 2009-10-07 2011-05-30 Egyt Gyogyszervegyeszeti Gyar Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
IT1400714B1 (it) 2010-07-06 2013-06-28 Chemelectiva S R L Processo ed intermedi per la preparazione di un principio attivo.
HU231050B1 (hu) 2010-08-19 2020-02-28 Egis Gyógyszergyár Nyrt. Eljárás gyógyszerhatóanyag előállítására
ITMI20112224A1 (it) 2011-12-06 2013-06-07 Chemelectiva S R L Nuovo processo ed intermedi per la sintesi di vildagliptin
IN2012MU01383A (da) * 2012-05-04 2014-02-28
CN103922986B (zh) * 2013-01-16 2017-02-15 上海彩迩文生化科技有限公司 维大列汀及其类似物、中间体及其制备方法和应用
WO2015145467A1 (en) * 2014-03-28 2015-10-01 Laurus Labs Private Limited An improved process for preparing vildagliptin
WO2021234430A1 (en) 2020-05-17 2021-11-25 Lotus International Pte. Ltd. Modified release dosage form comprising vildagliptin and process for manufacturing the same
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2001055105A1 (en) * 2000-01-24 2001-08-02 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
JP2002265439A (ja) * 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
PE20050021A1 (es) 2003-04-16 2005-03-15 Novartis Ag Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida

Also Published As

Publication number Publication date
PE20050021A1 (es) 2005-03-15
AU2008202278A1 (en) 2008-11-20
CA2520128C (en) 2012-02-07
DK1620396T3 (da) 2015-02-23
CL2004000804A1 (es) 2005-02-11
TW200510299A (en) 2005-03-16
BRPI0409471B8 (pt) 2021-05-25
RU2369598C2 (ru) 2009-10-10
BRPI0409471A (pt) 2006-05-02
US7375238B2 (en) 2008-05-20
KR20060003878A (ko) 2006-01-11
TWI359135B (en) 2012-03-01
NZ542899A (en) 2009-02-28
MXPA05011073A (es) 2005-12-12
NO20055226L (no) 2005-11-07
EP1620396A1 (en) 2006-02-01
RU2005135331A (ru) 2006-06-27
PT1620396E (pt) 2015-03-05
WO2004092127A1 (en) 2004-10-28
PL1620396T3 (pl) 2015-05-29
JP2006523645A (ja) 2006-10-19
HRP20150163T1 (en) 2015-03-27
US20060199854A1 (en) 2006-09-07
PE20081293A1 (es) 2008-11-04
AR044019A1 (es) 2005-08-24
NO333251B1 (no) 2013-04-22
EP1620396B1 (en) 2014-12-03
MY139476A (en) 2009-10-30
AU2004230245A1 (en) 2004-10-28
KR101192538B1 (ko) 2012-10-17
IS2979B (is) 2017-09-15
ECSP056093A (es) 2006-03-01
SI1620396T1 (sl) 2015-03-31
CO5700735A2 (es) 2006-11-30
JP4672647B2 (ja) 2011-04-20
HK1087695A1 (en) 2006-10-20
ES2531084T3 (es) 2015-03-10
AU2004230245B2 (en) 2008-02-21
CA2520128A1 (en) 2004-10-28
CY1116008T1 (el) 2017-01-25
BRPI0409471B1 (pt) 2015-11-03
MA27765A1 (fr) 2006-02-01
IS8122A (is) 2005-11-10
IL170887A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
NO20055226L (no) Fremgangsmate for fremstilling av N-substituerte 2-cyanopyrrolidoner
MXPA05008450A (es) Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
TW200635585A (en) Monocyclic substituted methanones
MX338829B (es) Metodo para preparar 3-halo-4,5-dihidro-1h-pirazoles.
TR200400238T4 (tr) ''Perindopril tert-bütilamin tuzunun alfa kristalin şekli''
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
EP1279665A3 (en) A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
HU0201083D0 (da)
TNSN05261A1 (en) Process for the preparation of n-substituted 2-cyanopyrrolidines
MXPA05011183A (es) Sintesis de 2-hidroxi-n, n-dimetil- 3-[[2-[1(r) -(5-metil -2-furanil) propil]amino]-3, 4-dioxo-1 -ciclobuten-1 -il]amino] benzamida.
EA200200807A1 (ru) Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece
ES2167869T3 (es) Procedimiento para preparar acidos nicotinicos.
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
IL162788A (en) Process for preparing a tripeptide and salt thereof
DE60306361D1 (de) Verfahren zur herstellung von benazeprilhydrochloride
CA2375631A1 (en) Process for production of amic acid ester
DE60137352D1 (de) Nsalze, verfahren zur herstellung von beiden und ihre verwendung
HUP0204009A2 (hu) 1. típusú nátrium-hidrogén csere (NHE-1) gátló kristályok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20040214885A1 (en) Ferrous bisglycinate hydrochloride
GB0008179D0 (en) Chemical process
DE50206142D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
DK1320527T3 (da) Fremgangsmåde til fremstilling af 1-substituerede 5-chlor-4-methylpytrazoler
BR0207895A (pt) Processo para a preparação de citalopram
NO20010332L (no) Nye derivater av 6-deoksyerytromycin, deres fremstillingsprosess og deres anvendelse som medikamenter